Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)’s traded shares stood at 1.16 million during the last session, with the company’s beta value hitting 1.79. At the close of trading, the stock’s price was $17.94, to imply a decrease of -0.61% or -$0.11 in intraday trading. The RYTM share’s 52-week high remains $34.99, putting it -95.04% down since that peak but still an impressive 83.05% since price per share fell to its 52-week low of $3.04. The company has a valuation of $1.09B, with an average of 0.86 million shares in intraday trading volume over the past 10 days and average of 607.71K shares over the past 3 months.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) trade information
After registering a -0.61% downside in the last session, Rhythm Pharmaceuticals Inc. (RYTM) has traded red over the past five days. The stock hit a weekly high of 19.94 this Friday, 03/17/23, dropping -0.61% in its intraday price action. The 5-day price performance for the stock is -8.47%, and -31.94% over 30 days. With these gigs, the year-to-date price performance is -38.39%. Short interest in Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) saw shorts transact 7.74 million shares and set a 12.45 days time to cover.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Rhythm Pharmaceuticals Inc. (RYTM) estimates and forecasts
Looking at statistics comparing Rhythm Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Rhythm Pharmaceuticals Inc. (RYTM) shares are -23.04% down over the last 6 months, with its year-to-date growth rate higher than industry average at 15.56% against 9.60%. Revenue is forecast to grow 4.70% this quarter before jumping 26.70% for the next one. The rating firms project that company’s revenue will grow 598.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is $7.03 million. Meanwhile, for the quarter ending Mar 2023, a total of 6 analyst(s) estimate revenue growth to $10.94 million.Earnings reports from the last fiscal year show that sales brought in $1.82 million and $1.5 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 286.90% before jumping 630.30% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -4.20% for the past 5-year period. While 2023 is set for a -147.60% return in earnings, projections for the next 5 years are at -9.00% annually.
Rhythm Pharmaceuticals Inc. has its next earnings report out between May 01 and May 05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Rhythm Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)’s Major holders
Rhythm Pharmaceuticals Inc. insiders hold 0.31% of total outstanding shares, with institutional holders owning 108.53% of the shares at 108.87% float percentage. In total, 108.53% institutions holds shares in the company, led by Primecap Management Company. As of Sep 29, 2022, the company held over 7.03 million shares (or 12.47% of shares), all amounting to roughly $172.16 million.
The next major institution holding the largest number of shares is Federated Hermes, Inc. with 6.31 million shares, or about 11.19% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $154.52 million.
We also have Primecap Odyssey Aggressive Growth Fund and Federated Hermes Kaufmann Fund as the top two Mutual Funds with the largest holdings of the Rhythm Pharmaceuticals Inc. (RYTM) shares. Going by data provided on Dec 30, 2022, Primecap Odyssey Aggressive Growth Fund holds roughly 4.89 million shares. This is just over 8.67% of the total shares, with a market valuation of $142.34 million. Data from the same date shows that the other fund manager holds a little less at 3.85 million, or 6.83% of the shares, all valued at about 96.83 million.